Cite
Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.
MLA
Beck, Hans-Peter, et al. “Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium Vivax Genotyping.” The Journal of Infectious Diseases, vol. 213, no. 5, Mar. 2016, pp. 794–99. EBSCOhost, https://doi.org/10.1093/infdis/jiv508.
APA
Beck, H.-P., Wampfler, R., Carter, N., Koh, G., Osorio, L., Rueangweerayut, R., Krudsood, S., Lacerda, M. V., Llanos-Cuentas, A., Duparc, S., Rubio, J. P., & Green, J. A. (2016). Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping. The Journal of Infectious Diseases, 213(5), 794–799. https://doi.org/10.1093/infdis/jiv508
Chicago
Beck, Hans-Peter, Rahel Wampfler, Nick Carter, Gavin Koh, Lyda Osorio, Ronnatrai Rueangweerayut, Srivcha Krudsood, et al. 2016. “Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium Vivax Genotyping.” The Journal of Infectious Diseases 213 (5): 794–99. doi:10.1093/infdis/jiv508.